MTOR and metabolic dysfunction-associated steatotic liver disease: The application of inhibitors of mTOR and other regulators implicated in NAFLD/NASH helped us better understand its orchestrating role and further allowed the discovery of novel potential biomarkers in NAFLD/NASH and HCC.